Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.12
PTX's Cash to Debt is ranked lower than
93% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. PTX: 0.12 )
Ranked among companies with meaningful Cash to Debt only.
PTX' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.79 Max: No Debt
Current: 0.12
Equity to Asset 0.02
PTX's Equity to Asset is ranked lower than
97% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. PTX: 0.02 )
Ranked among companies with meaningful Equity to Asset only.
PTX' s Equity to Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.43 Max: 0.83
Current: 0.02
0.02
0.83
F-Score: 4
Z-Score: -0.97
M-Score: -4.08
WACC vs ROIC
9.55%
-34.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -60.86
PTX's Operating margin (%) is ranked lower than
87% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. PTX: -60.86 )
Ranked among companies with meaningful Operating margin (%) only.
PTX' s Operating margin (%) Range Over the Past 10 Years
Min: -64.4  Med: -0.97 Max: 28.95
Current: -60.86
-64.4
28.95
Net-margin (%) -86.33
PTX's Net-margin (%) is ranked lower than
88% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. PTX: -86.33 )
Ranked among companies with meaningful Net-margin (%) only.
PTX' s Net-margin (%) Range Over the Past 10 Years
Min: -30.88  Med: -1.64 Max: 28.02
Current: -86.33
-30.88
28.02
ROE (%) -221.96
PTX's ROE (%) is ranked lower than
97% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. PTX: -221.96 )
Ranked among companies with meaningful ROE (%) only.
PTX' s ROE (%) Range Over the Past 10 Years
Min: -36.32  Med: -1.76 Max: 69.69
Current: -221.96
-36.32
69.69
ROA (%) -28.61
PTX's ROA (%) is ranked lower than
86% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. PTX: -28.61 )
Ranked among companies with meaningful ROA (%) only.
PTX' s ROA (%) Range Over the Past 10 Years
Min: -11.08  Med: -0.75 Max: 34.48
Current: -28.61
-11.08
34.48
ROC (Joel Greenblatt) (%) -1475.42
PTX's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. PTX: -1475.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PTX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -291.56  Med: -0.80 Max: 319.83
Current: -1475.42
-291.56
319.83
Revenue Growth (3Y)(%) 9.10
PTX's Revenue Growth (3Y)(%) is ranked higher than
61% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. PTX: 9.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PTX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -21.45 Max: 105.3
Current: 9.1
0
105.3
EBITDA Growth (3Y)(%) -51.10
PTX's EBITDA Growth (3Y)(%) is ranked lower than
96% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. PTX: -51.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PTX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -46.75 Max: 131.4
Current: -51.1
0
131.4
» PTX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

PTX Guru Trades in Q2 2015

Steven Cohen 525,000 sh (New)
Jim Simons 57,021 sh (New)
Paul Tudor Jones 75,800 sh (+53.13%)
» More
Q3 2015

PTX Guru Trades in Q3 2015

Jim Simons 463,602 sh (+713.04%)
Steven Cohen 1,050,005 sh (+100.00%)
Paul Tudor Jones Sold Out
» More
Q4 2015

PTX Guru Trades in Q4 2015

Paul Tudor Jones 16,134 sh (New)
Jim Simons 847,823 sh (+82.88%)
Steven Cohen 1,050,005 sh (unchged)
» More
Q1 2016

PTX Guru Trades in Q1 2016

Steven Cohen 2,500,000 sh (+138.09%)
Paul Tudor Jones Sold Out
Jim Simons 131,937 sh (-84.44%)
» More
» Details

Insider Trades

Latest Guru Trades with PTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:XPAE:PHARMACARE, ROCO:6467, NAS:ACUR, NAS:CBYL, ROCO:4127 » details
Traded in other countries:GTAP.Germany,
Pernix Therapeutics Holdings Inc is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for sleep, bacterial infections and cough and cold conditions.

Pernix Therapeutics Holdings Inc were incorporated in Maryland in November 1996. The Company is a specialty pharmaceutical company that sells, markets, manufactures and develops a number of branded and generic pharmaceutical products primarily indicated for sleep, bacterial infections and cough and cold conditions. The Company branded products includes CEDAX, an antibiotic for middle ear infections, and a family of prescription treatments for cough and cold. The Company also market SILENOR (doxepin), which is approved for the treatment of insomnia characterized by difficulty with sleep maintenance and is not a controlled substance. The Company also currently promotes Omeclamox-Pak through a License and Supply Agreement with GastroEntero-Logic, LLC; as entered into a promotion agreement with Cumberland Pharmaceuticals pursuant to which Cumberland began promoting Omeclamox-Pak to gastroenterologists. The Company also entered into an Exclusive License Agreement with Osmotica Pharmaceutical Corp. to promote its desvenlafaxine product, Khedezla Extended-Release Tablets, 50 and 100 mg. It sells its generic products in the areas of cough and cold, pain, vitamins, dermatology, antibiotics and gastroenterology through its wholly-owned subsidiaries. The Companys branded product portfolio includes; SILENOR; KHEDEZLA; CEDAX; ZUTRIPRO; REZIRA; VITUZ; and OMECLAMOX-PAK. The products of the Company face competition from a variety of similar therapeutic branded and generic products. The Companys product candidates and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the DEA and other regulatory agencies in the United States and by comparable European authorities.

Ratios

vs
industry
vs
history
Forward P/E 1.87
PTX's Forward P/E is ranked higher than
99% of the 90 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.95 vs. PTX: 1.87 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.13
PTX's P/B is ranked lower than
52% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. PTX: 3.13 )
Ranked among companies with meaningful P/B only.
PTX' s P/B Range Over the Past 10 Years
Min: 0.26  Med: 1.64 Max: 16.1
Current: 3.13
0.26
16.1
P/S 0.17
PTX's P/S is ranked higher than
98% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. PTX: 0.17 )
Ranked among companies with meaningful P/S only.
PTX' s P/S Range Over the Past 10 Years
Min: 0.07  Med: 1.33 Max: 10.57
Current: 0.17
0.07
10.57
PFCF 48.89
PTX's PFCF is ranked lower than
65% of the 199 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.71 vs. PTX: 48.89 )
Ranked among companies with meaningful PFCF only.
PTX' s PFCF Range Over the Past 10 Years
Min: 5.92  Med: 32.35 Max: 434.62
Current: 48.89
5.92
434.62
POCF 13.78
PTX's POCF is ranked higher than
67% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. PTX: 13.78 )
Ranked among companies with meaningful POCF only.
PTX' s POCF Range Over the Past 10 Years
Min: 5.49  Med: 28.38 Max: 183.33
Current: 13.78
5.49
183.33
EV-to-EBITDA 17.03
PTX's EV-to-EBITDA is ranked higher than
50% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. PTX: 17.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -80.6  Med: 11.10 Max: 280.5
Current: 17.03
-80.6
280.5
Current Ratio 1.07
PTX's Current Ratio is ranked lower than
86% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. PTX: 1.07 )
Ranked among companies with meaningful Current Ratio only.
PTX' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.79 Max: 64.5
Current: 1.07
0.84
64.5
Quick Ratio 0.97
PTX's Quick Ratio is ranked lower than
77% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. PTX: 0.97 )
Ranked among companies with meaningful Quick Ratio only.
PTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.59 Max: 64.5
Current: 0.97
0.62
64.5
Days Inventory 76.91
PTX's Days Inventory is ranked higher than
72% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. PTX: 76.91 )
Ranked among companies with meaningful Days Inventory only.
PTX' s Days Inventory Range Over the Past 10 Years
Min: 92.49  Med: 146.79 Max: 220.74
Current: 76.91
92.49
220.74
Days Sales Outstanding 108.30
PTX's Days Sales Outstanding is ranked lower than
73% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. PTX: 108.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
PTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.95  Med: 124.07 Max: 218.16
Current: 108.3
22.95
218.16
Days Payable 99.66
PTX's Days Payable is ranked higher than
68% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.47 vs. PTX: 99.66 )
Ranked among companies with meaningful Days Payable only.
PTX' s Days Payable Range Over the Past 10 Years
Min: 28.65  Med: 78.77 Max: 126.23
Current: 99.66
28.65
126.23

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.11
PTX's Price/Median PS Value is ranked higher than
99% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. PTX: 0.11 )
Ranked among companies with meaningful Price/Median PS Value only.
PTX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.08  Med: 1.49 Max: 7.41
Current: 0.11
0.08
7.41
Earnings Yield (Greenblatt) (%) -34.30
PTX's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. PTX: -34.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PTX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -34.57  Med: 4.30 Max: 12.2
Current: -34.3
-34.57
12.2

More Statistics

Revenue (TTM) (Mil) $174.4
EPS (TTM) $ -2.56
Beta2.43
Short Percentage of Float11.26%
52-Week Range $0.39 - 6.49
Shares Outstanding (Mil)61.13

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 163 188 217
EPS ($) -0.14 0.24 0.39
EPS without NRI ($) -0.14 0.24 0.39
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for PTX

Headlines

Articles On GuruFocus.com
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Nov 12 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Aug 16 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and... May 26 2016
Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro® ER with... May 25 2016
Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro® ER with... May 25 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... May 19 2016
ETF’s with exposure to Pernix Therapeutics Holdings, Inc. : May 19, 2016 May 18 2016
Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Financials May 13 2016
Pernix Therapeutics Names John Sedor As Chairman and Interim CEO In Place Of Dough Drysdale May 11 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... May 11 2016
Pernix Therapeutics Announces CEO Transition May 11 2016
Pernix Therapeutics Overcomes Challenge to Treximet® ‘183 Patent May 10 2016
Pernix Therapeutics Overcomes Challenge to Treximet® ‘183 Patent May 09 2016
Is Pernix Therapeutics in a Race to Zero? May 05 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report May 05 2016
Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update May 05 2016
Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update May 05 2016
Q1 2016 Pernix Therapeutics Holdings Inc Earnings Release - Before Market Open May 05 2016
ETF’s with exposure to Pernix Therapeutics Holdings, Inc. : May 3, 2016 May 03 2016
This Pharma Company is Soaring After Steve Cohen Boosts Stake, GrubHub Inc. (GRUB) Has a Bullish New... May 02 2016
Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016 Apr 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)